Franklin Genomic Advancements ETF Rating $28.04 +0.89 (+3.27%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartHoldingsOwnershipRatingsBuy This Stock Franklin Genomic Advancements ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.HELX Aggregate RatingModerate Buy 2.76Holdings in HELX have an aggregate rating of Moderate Buy based on 659 analyst ratings issued in the past year covering 45 companies (85.0% of the portfolio).HELX Aggregate Price Target$28.05High Prediction$28.05Average Prediction$28.05Low Prediction$28.05Holdings in HELX have an aggregate price target of $28.05 and a range of $28.05 to $28.05 covering 45 companies (85.0% of the portfolio).HELX Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy7 Buy rating(s)Moderate Buy31 Moderate Buy rating(s)Hold7 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Franklin Genomic Advancements ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 45 HELX Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings6.46%NTRANatera$161.500.0%2.1148 of 5 stars3.00$184.63 14.3%15Positive News4.16%VRTXVertex Pharmaceuticals$454.64-0.5%4.7682 of 5 stars2.54$511.62 12.5%28Positive News3.60%GHGuardant Health$50.25+0.1%3.8563 of 5 stars3.00$53.76 7.0%213.56%ALNYAlnylam Pharmaceuticals$331.94+0.7%4.2152 of 5 stars2.79$340.00 2.4%24Positive NewsAnalyst Upgrade3.54%MEDPMedpace$321.50-1.4%4.4638 of 5 stars2.21$344.82 7.3%143.38%KRYSKrystal Biotech$143.01+1.2%4.5874 of 5 stars3.00$211.13 47.6%93.33%CTVACorteva$77.24+0.3%4.3663 of 5 stars2.79$72.08 -6.7%14Positive News3.32%INSMInsmed$98.50+0.3%4.1471 of 5 stars3.00$106.80 8.4%17Positive News3.23%LLYEli Lilly and Company$779.60+0.0%4.9884 of 5 stars2.75$1,011.61 29.8%20Trending News2.88%UTHRUnited Therapeutics$294.57-0.2%4.9954 of 5 stars2.69$386.15 31.1%13Positive News2.86%BNTXBioNTech$109.65+1.3%2.3131 of 5 stars2.83$137.86 25.7%182.79%AZNAstraZeneca$69.60-2.2%2.3041 of 5 stars2.83$85.00 22.1%6Positive News2.54%REGNRegeneron Pharmaceuticals$545.00-0.5%4.9552 of 5 stars2.80$813.57 49.3%252.29%CDNSCadence Design Systems$328.49+5.6%4.1564 of 5 stars2.77$325.23 -1.0%13Trending NewsGap Up2.29%BBIOBridgeBio Pharma$43.71+2.0%4.6879 of 5 stars2.93$58.85 34.6%142.10%TMOThermo Fisher Scientific$428.25+0.1%4.9938 of 5 stars2.80$604.05 41.1%20Positive News1.91%RAREUltragenyx Pharmaceutical$39.19-0.7%3.9849 of 5 stars2.93$87.00 122.0%141.88%DHRDanaher$203.08+0.3%4.8656 of 5 stars2.80$248.61 22.4%20Positive News1.84%EXASExact Sciences$52.82-1.9%4.939 of 5 stars2.95$70.40 33.3%22Positive News1.79%ADPTAdaptive Biotechnologies$11.98+4.3%3.4363 of 5 stars2.86$10.57 -11.7%7Gap Up1.78%QGENQIAGEN$48.34-0.6%3.9207 of 5 stars2.30$49.40 2.2%10Dividend Announcement1.72%TWSTTwist Bioscience$38.11+1.1%4.4676 of 5 stars2.70$50.40 32.2%10Positive News1.70%TEMTempus AI$60.65+2.5%2.0808 of 5 stars2.54$63.67 5.0%13Trending NewsGap Down1.61%LGNDLigand Pharmaceuticals$114.39+0.6%4.8114 of 5 stars3.00$146.14 27.8%71.48%LHLabcorp$261.89+0.7%4.4608 of 5 stars2.79$276.08 5.4%14Positive News1.33%CRLCharles River Laboratories International$157.12-0.2%4.0771 of 5 stars2.19$171.85 9.4%16News CoveragePositive NewsAnalyst Downgrade1.31%AAgilent Technologies$121.16+0.4%4.742 of 5 stars2.54$140.92 16.3%13Positive News1.19%RGENRepligen$127.36+0.3%4.7713 of 5 stars2.69$172.83 35.7%13Positive News1.16%NBIXNeurocrine Biosciences$128.04-1.1%4.9212 of 5 stars2.86$162.00 26.5%22Positive News1.08%DOCSDoximity$61.69+4.0%2.4903 of 5 stars2.59$63.11 2.3%22Positive News1.06%GRALGRAIL$46.81-1.6%0.6498 of 5 stars2.25$31.50 -32.7%4Positive News0.97%BMRNBioMarin Pharmaceutical$57.25+0.1%4.9444 of 5 stars2.75$93.61 63.5%240.91%CPRXCatalyst Pharmaceuticals$21.64+0.9%4.898 of 5 stars3.25$32.83 51.7%80.88%IQVIQVIA$164.24-0.2%4.8872 of 5 stars2.75$226.32 37.8%240.85%VCYTVeracyte$27.51-0.3%3.7566 of 5 stars2.70$40.90 48.7%100.76%RXRXRecursion Pharmaceuticals$5.26+1.0%1.7586 of 5 stars2.33$7.00 33.1%60.75%RVTYRevvity$101.31+0.4%3.5252 of 5 stars2.80$123.64 22.0%15Positive News0.70%PTCTPTC Therapeutics$48.77-0.8%4.3117 of 5 stars2.67$65.00 33.3%150.65%IONSIonis Pharmaceuticals$42.98-1.4%4.6749 of 5 stars2.78$58.25 35.5%180.62%DVAXDynavax Technologies$10.28+1.2%4.3926 of 5 stars2.50$24.00 133.5%4Positive News0.60%SDGRSchrodinger$20.962.7908 of 5 stars2.75$33.25 58.6%40.58%BEAMBeam Therapeutics$20.02+0.7%2.4892 of 5 stars3.00$48.75 143.5%150.57%BRKRBruker$42.42-0.1%4.776 of 5 stars2.40$52.89 24.7%10Positive News0.51%BMYBristol Myers Squibb$47.02-1.3%4.9467 of 5 stars2.32$58.00 23.4%22Positive News0.50%CDNACareDx$19.20-1.5%4.4398 of 5 stars2.67$30.33 58.0%6Positive News This page (BATS:HELX) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Franklin Genomic Advancements ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Franklin Genomic Advancements ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
